BELLEROPHON THERAPEUTICS, INC. Financials Bellerophon Therapeutics, Inc. Börse Stuttgart
Equities
6L7A
US0787713009
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.421 EUR | +20.98% |
|
+26.05% | -45.08% |
| 25/04 | North American Morning Briefing : More Tech -2- | DJ |
| 11/04 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 142.4 | 47.03 | 24.03 | 63.35 | 29.47 | 8.591 |
| Enterprise Value (EV) 1 | 110.5 | 30.38 | 16.47 | 17.45 | 5.689 | 1.87 |
| P/E ratio | -0.12 x | 1.09 x | -1.78 x | -2.1 x | -1.66 x | -0.43 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -4.56 x | -1.1 x | -0.96 x | -0.84 x | -0.29 x | -0.08 x |
| EV / FCF | -12.8 x | -2.86 x | -1.87 x | -2.04 x | -0.34 x | -0.15 x |
| FCF Yield | -7.78% | -35% | -53.4% | -48.9% | -294% | -650% |
| Price to Book | -56.6 x | 12.2 x | 6.69 x | 1.66 x | 1.37 x | 3.43 x |
| Nbr of stocks (in thousands) | 3,679 | 3,912 | 4,580 | 9,498 | 9,506 | 9,545 |
| Reference price 2 | 38.70 | 12.02 | 5.246 | 6.670 | 3.100 | 0.9000 |
| Announcement Date | 15/03/18 | 14/03/19 | 06/04/20 | 11/03/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -24.23 | -27.52 | -17.12 | -20.83 | -19.65 | -22.32 |
| EBIT 1 | -24.6 | -27.88 | -17.47 | -20.98 | -19.75 | -22.39 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -54.82 | -2.625 | -15.07 | -26.85 | -19.56 | -22.25 |
| Net income 1 | -54.82 | 2.814 | -13.27 | -24.73 | -17.76 | -19.83 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -316.7 | 11.02 | -2.950 | -3.171 | -1.870 | -2.080 |
| Free Cash Flow 1 | -8.605 | -10.64 | -8.791 | -8.542 | -16.74 | -12.16 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 15/03/18 | 14/03/19 | 06/04/20 | 11/03/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 5.64 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.226 | -4.803 | -4.273 | -5.642 | -6.541 | -5.116 | -5.085 | 1.479 | -5.259 | -2.17 |
| Operating Margin | - | - | - | - | - | - | - | 26.22% | - | - |
| Earnings before Tax (EBT) 1 | -5.189 | -4.634 | -4.272 | -5.641 | -6.522 | -5.069 | -5.016 | 1.545 | -5.138 | -1.921 |
| Net income 1 | -3.389 | -4.634 | -4.272 | -5.641 | -4.105 | -5.069 | -5.016 | 2.822 | -5.138 | -1.921 |
| Net margin | - | - | - | - | - | - | - | 50.04% | - | - |
| EPS 2 | -0.3600 | -0.4900 | -0.4500 | -0.5900 | -0.4300 | -0.5300 | -0.5300 | 0.2700 | -0.4200 | -0.1600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 05/08/21 | 15/11/21 | 31/03/22 | 11/05/22 | 15/08/22 | 14/11/22 | 31/03/23 | 15/05/23 | 14/08/23 | 14/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 31.8 | 16.6 | 7.56 | 45.9 | 23.8 | 6.72 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.61 | -10.6 | -8.79 | -8.54 | -16.7 | -12.2 |
| ROE (net income / shareholders' equity) | -712% | 446% | -356% | -118% | -59.3% | -164% |
| ROA (Net income/ Total Assets) | -46.2% | -63.2% | -69.4% | -41.4% | -32% | -80.4% |
| Assets 1 | 118.6 | -4.455 | 19.11 | 59.74 | 55.46 | 24.67 |
| Book Value Per Share 2 | -0.6800 | 0.9900 | 0.7800 | 4.030 | 2.260 | 0.2600 |
| Cash Flow per Share 2 | 7.600 | 4.250 | 2.160 | 5.010 | 2.590 | 0.7200 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 15/03/18 | 14/03/19 | 06/04/20 | 11/03/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0513
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +3.78% | 22.25B | |
| -14.77% | 21.68B | |
| -9.05% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- BLPH Stock
- 6L7A Stock
- Financials Bellerophon Therapeutics, Inc.
